Moderna, Inc. Common Stock
Here’s whether Moderna, Inc. Common Stock (MRNA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+14.01% over 10 days); strong 1-year return of +453.5%; 3-month momentum positive (+209.6%); rising volume confirms the move (2.41x 30d avg). Concerns: RSI 75 — overbought, elevated pullback risk. Currently 17.9% off its 52-week high. Score: +6/7.
MRNA is in a confirmed uptrend, trading above both its 50-day ($67.60) and 200-day ($48.73) moving averages. With an RSI of 74.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +453.5% compares to +20.5% for SPY (beat the market by 433.0%).